Clinical Trial Update: Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF [Phase 1]

View source ↗

Summary

Phase I trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AGMB-447 in healthy participants and individuals with idiopathic pulmonar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• AGMB-447 (AGMB-447)

Snippet

Sponsor: Agomab Spain S.L. | Conditions: IPF | Phase 1 | Status: RECRUITING